About Bladder Cancer Therapeutics
The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the innermost layer called urothelium or transitional epithelium, composed of epithelium or transitional cells.
Technavio’s analysts forecast the global bladder cancer therapeutics market to grow at a CAGR of 4.77% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global bladder cancer therapeutics market for 2017-2021. To calculate the market size, the report considers the sales from both branded and generic drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Bladder Cancer Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Bristol-Myers Squibb
• Eli Lilly
• F. Hoffman-La Roche
• Pfizer
Other prominent vendors
• Accord Healthcare
• AstraZeneca
• Bedford Lab
• Merck
• Sanofi
Market driver
• Growing prevalence rate leads to higher prescription value
• For a full, detailed list, view our report
Market challenge
• Economic burden of bladder cancer
• For a full, detailed list, view our report
Market trend
• Advent of novel pipeline
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Market outline
• Bladder
• Bladder cancer
• Currently approved therapeutic regimen
• Stages of bladder cancer
PART 05: Key clinical trials
PART 06: Market landscape
• Market size and forecast
• Five forces analysis
PART 07: Market segmentation by therapy
• Intravesical therapy
• Chemotherapy
• Preservation therapy
• Others
PART 08: Geographical segmentation
• Bladder cancer therapeutics market in Americas
• Bladder cancer therapeutics market in EMEA
• Bladder cancer therapeutics market in APAC
PART 09: Decision framework
PART 10: Drivers and challenges
• Market drivers
• Market challenges
PART 11: Market trends
• Growing influence of targeted biologics
• Advent of novel pipeline
• Emergence of effective diagnostic tools
PART 12: Vendor landscape
• Competitive landscape
PART 13: Key vendor analysis
• Bristol-Myers Squibb
• Eli Lilly
• F. Hoffman-La Roche
• Pfizer
• Other prominent vendors
PART 14: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Approved therapeutics for the treatment of bladder cancer
Exhibit 02: Stages of bladder cancer
Exhibit 03: Pipeline landscape based on development phase 2016
Exhibit 04: Key clinical trials
Exhibit 05: Snapshot of therapy-based pipeline in global bladder cancer market
Exhibit 06: Market scenario for global bladder cancer therapeutics market 2016-2021 ($ million)
Exhibit 07: Global bladder cancer therapeutics market revenue 2016-2021 ($ millions)
Exhibit 08: Opportunity analysis of global bladder cancer therapeutics market
Exhibit 09: Five forces analysis
Exhibit 10: Segmentation of global bladder cancer therapeutics market by therapy 2016
Exhibit 11: Global bladder cancer therapeutics market segmentation based on therapy 2016 (%)
Exhibit 12: Global bladder cancer therapeutics market for intravesical therapy 2016-2021 ($ millions)
Exhibit 13: Global bladder cancer therapeutics market for chemotherapy 2016-2021 ($ millions)
Exhibit 14: Global bladder cancer therapeutics market for preservation therapy 2016-2021 ($ millions)
Exhibit 15: Segmentation of global bladder cancer therapeutics market based on geography 2016 and 2021
Exhibit 16: Global bladder cancer therapeutics market revenue by geography 2016-2021 ($ millions)
Exhibit 17: Global bladder cancer therapeutics market share by geography 2016-2021 (%)
Exhibit 18: Market scenario in Americas
Exhibit 19: Bladder cancer therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 20: Market scenario in EMEA
Exhibit 21: Bladder cancer therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 22: Market scenario in APAC
Exhibit 23: Bladder cancer therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 24: Competitive structure analysis of global bladder cancer therapeutics market 2016
Exhibit 25: Bristol-Myers Squibb: Key highlights
Exhibit 26: Bristol-Myers Squibb: Strength assessment
Exhibit 27: Bristol-Myers Squibb: Strategy assessment
Exhibit 28: Bristol-Myers Squibb: Opportunity assessment
Exhibit 29: Eli Lilly: Key highlights
Exhibit 30: Eli Lilly: Strength assessment
Exhibit 31: Eli Lilly: Strategy assessment
Exhibit 32: Eli Lilly: Opportunity assessment
Exhibit 33: F. Hoffman-La Roche: Key highlights
Exhibit 34: F. Hoffman-La Roche: Strength assessment
Exhibit 35: F. Hoffman-La Roche: Strategy assessment
Exhibit 36: F. Hoffman-La Roche: Opportunity assessment
Exhibit 37: Pfizer: Key highlights
Exhibit 38: Pfizer: Strength assessment
Exhibit 39: Pfizer: Strategy assessment
Exhibit 40: Pfizer: Opportunity assessment
